Boiron SA
PAR:BOI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.2), the stock would be worth €34.17 (25% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.9 | €27.4 |
0%
|
| 3-Year Average | 1.2 | €34.17 |
+25%
|
| 5-Year Average | 1.3 | €37.55 |
+37%
|
| Industry Average | 1.7 | €49.08 |
+79%
|
| Country Average | 1 | €29.35 |
+7%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
€474.9m
|
/ |
Jul 2025
€504.9m
|
= |
|
|
€474.9m
|
/ |
Dec 2025
€528.2m
|
= |
|
|
€474.9m
|
/ |
Dec 2026
€528.2m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Boiron SA
PAR:BOI
|
475.7m EUR | 0.9 | 24.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 13.5 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 5.7 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 4.7 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 5 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 4.2 | 14.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 2.4 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2.5 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.5 |
| Median | 1 |
| 70th Percentile | 2.1 |
| Max | 34 178 916.3 |
Other Multiples
Boiron SA
Glance View
Boiron SA engages in the manufacturing and selling homeopathic medicines. The company is headquartered in Rontalon, Auvergne-Rhone-Alpes. The firm develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. The company also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
